Sequential treatment of tyrosine kinase inhibitor and platinum-based doublet chemotherapy on EGFR mutant non-small cell lung cancer: a meta-analysis of randomized controlled clinical trials

Lifen Qiao1 Department of Geriatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China;2 Cancer Center, Medical College of Wisconsin, Milwaukee, WI, USA

Jin Wang2 Cancer Center, Medical College of Wisconsin, Milwaukee, WI, USA;3 Department of Emergency

Guoxian Long2 Cancer Center, Medical College of Wisconsin, Milwaukee, WI, USA;4 Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Yueqiang Jiang1 Department of Geriatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China;5 Department of Toxicology and Pharmacology, Medical College of Wisconsin, Milwaukee, WI, USACorrespondence[email protected]

Citations (4)

Keep up to date with the latest research on this topic with citation updates for this article.

Sequential treatment of tyrosine kinase inhibitor and platinum-based doublet chemotherapy on EGFR mutant non-small cell lung cancer: a meta-analysis of randomized controlled clinical trials

Articles from other publishers (4)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Sequential treatment of tyrosine kinase inhibitor and platinum-based doublet chemotherapy on EGFR mutant non-small cell lung cancer: a meta-analysis of randomized controlled clinical trials

Citations (4)

Articles from other publishers (4)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date